tirzepatide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 5516 2023788-19-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tirzepatide
  • mounjaro
  • LY3298176
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.
  • Molecular weight: 4813.53
  • Formula: C225H348N48O68
  • CLOGP:
  • LIPINSKI: 3
  • HAC: 116
  • HDO: 58
  • TPSA: 1789.63
  • ALOGS:
  • ROTB: 163

Drug dosage:

DoseUnitRoute
1.40 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 13, 2022 FDA ELI LILLY CO
Sept. 15, 2022 EMA ELI LILLY NEDERLAND B.V.
Sept. 26, 2022 PMDA ELI LILLY JAPAN K.K

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incorrect dose administered 1669.49 20.05 585 14253 78345 90535264
Injection site pain 758.14 20.05 425 14413 173274 90440335
Extra dose administered 548.36 20.05 151 14687 8967 90604642
Accidental underdose 360.29 20.05 72 14766 1019 90612590
Injection site erythema 325.91 20.05 202 14636 98300 90515309
Nausea 249.90 20.05 554 14284 1109762 89503847
Injection site pruritus 242.76 20.05 135 14703 53699 90559910
Injection site haemorrhage 202.88 20.05 97 14741 28221 90585388
Injection site rash 195.38 20.05 90 14748 24083 90589526
Product administered at inappropriate site 165.67 20.05 50 14788 4101 90609508
Injection site bruising 142.42 20.05 95 14743 52212 90561397
Injection site urticaria 136.03 20.05 64 14774 17947 90595662
Eructation 125.30 20.05 52 14786 10830 90602779
Injury associated with device 124.90 20.05 41 14797 4423 90609186
Dermatitis atopic 119.98 20.05 64 14774 23408 90590201
Vomiting 113.12 20.05 333 14505 787960 89825649
Illness 110.51 20.05 98 14740 81871 90531738
Injection site reaction 110.27 20.05 103 14735 91977 90521632
Injection site injury 105.97 20.05 26 14812 973 90612636
Off label use 102.93 20.05 403 14435 1101849 89511760
Product dose omission issue 101.88 20.05 176 14662 291511 90322098
Impaired gastric emptying 95.13 20.05 45 14793 12764 90600845
Injection site swelling 91.70 20.05 77 14761 59762 90553847
Product tampering 80.55 20.05 18 14820 445 90613164
Hunger 77.71 20.05 32 14806 6531 90607078
Constipation 71.51 20.05 148 14690 280247 90333362
Glycosylated haemoglobin increased 70.00 20.05 39 14799 15523 90598086
Blood glucose increased 68.19 20.05 81 14757 95165 90518444
Injection site hypersensitivity 64.52 20.05 22 14816 2665 90610944
Inappropriate schedule of product administration 63.79 20.05 99 14739 149834 90463775
Intercepted product dispensing error 61.63 20.05 12 14826 147 90613462
Hypoglycaemia 57.75 20.05 64 14774 69784 90543825
Injection site mass 57.40 20.05 39 14799 22051 90591558
Increased appetite 57.09 20.05 31 14807 11734 90601875
Exposure via skin contact 54.16 20.05 29 14809 10676 90602933
Dry skin 51.98 20.05 68 14770 88005 90525604
Ketoacidosis 48.86 20.05 22 14816 5573 90608036
Blood glucose decreased 48.48 20.05 36 14802 23393 90590216
Feeding disorder 48.09 20.05 32 14806 17480 90596129
Arthropathy 48.09 20.05 3 14835 366239 90247370
Pruritus 47.74 20.05 195 14643 541330 90072279
Accidental overdose 46.67 20.05 38 14800 28235 90585374
Infusion related reaction 41.12 20.05 9 14829 416771 90196838
Optic ischaemic neuropathy 40.72 20.05 14 14824 1738 90611871
Euglycaemic diabetic ketoacidosis 40.64 20.05 20 14818 6181 90607428
Starvation ketoacidosis 40.53 20.05 9 14829 216 90613393
Colitis ischaemic 39.92 20.05 25 14813 12321 90601288
Systemic lupus erythematosus 39.61 20.05 6 14832 361890 90251719
Intestinal ischaemia 39.23 20.05 22 14816 8861 90604748
Injection site irritation 38.23 20.05 19 14819 5996 90607613
Diarrhoea 36.81 20.05 271 14567 938919 89674690
General physical health deterioration 36.41 20.05 7 14831 355108 90258501
Postmenopausal haemorrhage 36.25 20.05 14 14824 2416 90611193
Pyrexia 36.16 20.05 33 14805 660452 89953157
Accidental exposure to product 35.32 20.05 39 14799 42327 90571282
Sleep disorder due to a general medical condition 35.27 20.05 40 14798 44698 90568911
Eye irritation 34.97 20.05 35 14803 33943 90579666
Product dose omission in error 34.77 20.05 28 14810 20475 90593134
Joint swelling 34.22 20.05 20 14818 503280 90110329
Neurodermatitis 33.23 20.05 14 14824 3024 90610585
Wound 33.20 20.05 5 14833 302975 90310634
Product use issue 32.79 20.05 7 14831 329912 90283697
Dehydration 32.40 20.05 87 14751 194360 90419249
Pancreatitis 32.35 20.05 48 14790 69778 90543831
Sensitive skin 31.79 20.05 14 14824 3367 90610242
Food craving 31.74 20.05 12 14826 1955 90611654
Cholelithiasis 31.68 20.05 41 14797 52465 90561144
Depressed mood 31.54 20.05 40 14798 50182 90563427
Weight decreased 31.22 20.05 134 14704 379776 90233833
Abdominal pain 30.56 20.05 137 14701 395584 90218025
Pneumonia 30.27 20.05 36 14802 638023 89975586
Lower respiratory tract infection 30.24 20.05 3 14835 250656 90362953
Small intestinal obstruction 29.81 20.05 26 14812 21208 90592401
Treatment failure 29.09 20.05 7 14831 303921 90309688
Skin exfoliation 29.07 20.05 45 14793 67868 90545741
Confusional state 28.20 20.05 14 14824 386191 90227418
Skin swelling 28.18 20.05 16 14822 6598 90607011
Anaemia 26.98 20.05 12 14826 352790 90260819
Diabetic ketoacidosis 26.71 20.05 26 14812 24381 90589228
Neutropenia 26.34 20.05 3 14835 224901 90388708
Eczema 25.43 20.05 37 14801 52833 90560776
Therapeutic product effect decreased 25.40 20.05 7 14831 277564 90336045
Impaired healing 25.34 20.05 4 14834 234195 90379414
Swelling 25.30 20.05 19 14819 419039 90194570
Toxicity to various agents 24.99 20.05 8 14830 287838 90325771
Injection site discomfort 24.32 20.05 14 14824 5926 90607683
Product preparation error 24.03 20.05 17 14821 10244 90603365
Thrombocytopenia 23.91 20.05 3 14835 208722 90404887
Injection site warmth 23.69 20.05 21 14817 17494 90596115
Intentional dose omission 23.42 20.05 21 14817 17762 90595847
Stomatitis 23.21 20.05 8 14830 274690 90338919
Injection site vesicles 23.01 20.05 12 14826 4188 90609421
COVID-19 22.74 20.05 70 14768 168773 90444836
Oedema 22.65 20.05 3 14835 200292 90413317
Injury 22.21 20.05 3 14835 197346 90416263
Exposure during pregnancy 21.83 20.05 6 14832 238404 90375205
Food interaction 21.45 20.05 8 14830 1256 90612353
Irritable bowel syndrome 21.44 20.05 4 14834 207444 90406165
Contraindicated product administered 21.34 20.05 13 14825 320126 90293483
Musculoskeletal stiffness 21.27 20.05 11 14827 296521 90317088
Thyroid cancer 21.01 20.05 13 14825 6271 90607338
Fluid intake reduced 20.31 20.05 11 14827 4141 90609468

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incorrect dose administered 350.20 26.07 160 5457 52814 42562904
Injection site pain 225.17 26.07 122 5495 57676 42558042
Extra dose administered 178.15 26.07 54 5563 5615 42610103
Diarrhoea 108.25 26.07 206 5411 460643 42155075
Vomiting 105.87 26.07 158 5459 289565 42326153
Accidental underdose 105.04 26.07 23 5594 648 42615070
Injection site haemorrhage 88.54 26.07 39 5578 11697 42604021
Nausea 86.38 26.07 172 5445 396627 42219091
Eructation 86.31 26.07 31 5586 5455 42610263
Injection site erythema 82.25 26.07 44 5573 20151 42595567
Injection site rash 70.47 26.07 27 5590 5685 42610033
Flatulence 53.28 26.07 36 5581 25116 42590602
Injection site pruritus 48.41 26.07 24 5593 9381 42606337
Pancreatitis 47.69 26.07 42 5575 43226 42572492
Constipation 47.23 26.07 80 5537 162211 42453507
Euglycaemic diabetic ketoacidosis 46.56 26.07 20 5597 5640 42610078
Dermatitis atopic 44.87 26.07 25 5592 12379 42603339
Optic ischaemic neuropathy 44.84 26.07 16 5601 2759 42612959
Glycosylated haemoglobin increased 43.91 26.07 25 5592 12899 42602819
Injection site injury 43.08 26.07 10 5607 368 42615350
Blood glucose increased 41.79 26.07 50 5567 73649 42542069
Inappropriate schedule of product administration 41.67 26.07 57 5560 95845 42519873
Impaired gastric emptying 41.16 26.07 17 5600 4349 42611369
Injection site swelling 40.07 26.07 26 5591 16947 42598771
Injection site mass 32.98 26.07 18 5599 8557 42607161
Diabetic ketoacidosis 31.44 26.07 25 5592 22342 42593376
Injection site bruising 30.55 26.07 19 5598 11506 42604212
Small intestinal obstruction 30.46 26.07 22 5595 17039 42598679
Exposure via skin contact 29.36 26.07 14 5603 5024 42610694
Systolic hypertension 28.21 26.07 7 5610 343 42615375
Injection site urticaria 27.97 26.07 12 5605 3371 42612347
Product tampering 27.69 26.07 5 5612 50 42615668
Pneumonia 26.98 26.07 11 5606 422138 42193580
Lipase increased 26.95 26.07 17 5600 10549 42605169
Aura 26.86 26.07 7 5610 418 42615300
Hypoglycaemia 26.61 26.07 36 5581 59818 42555900
Accidental overdose 26.31 26.07 25 5592 28305 42587413
Gastrooesophageal reflux disease 26.24 26.07 31 5586 44992 42570726

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incorrect dose administered 1982.72 19.38 701 16273 102940 110469385
Injection site pain 866.24 19.38 458 16516 177464 110394861
Extra dose administered 709.88 19.38 194 16780 11965 110560360
Accidental underdose 472.38 19.38 92 16882 1213 110571112
Injection site erythema 319.99 19.38 192 16782 93984 110478341
Nausea 292.82 19.38 606 16368 1235084 109337241
Injection site haemorrhage 281.13 19.38 125 16849 32903 110539422
Injection site pruritus 193.63 19.38 112 16862 51146 110521179
Vomiting 174.26 19.38 411 16563 910264 109662061
Injection site bruising 149.74 19.38 95 16879 51168 110521157
Injection site injury 146.46 19.38 34 16940 1070 110571255
Eructation 145.12 19.38 61 16913 13996 110558329
Injection site rash 144.54 19.38 71 16903 23348 110548977
Dermatitis atopic 121.57 19.38 65 16909 25476 110546849
Injection site urticaria 120.80 19.38 57 16917 17158 110555167
Product dose omission issue 120.05 19.38 193 16781 321589 110250736
Impaired gastric emptying 112.12 19.38 50 16924 13225 110559100
Diarrhoea 98.22 19.38 389 16585 1139116 109433209
Glycosylated haemoglobin increased 95.56 19.38 54 16920 23565 110548760
Constipation 90.27 19.38 181 16793 357605 110214720
Injection site swelling 85.59 19.38 73 16901 61717 110510608
Injection site reaction 84.15 19.38 85 16889 88985 110483340
Product administered at inappropriate site 82.17 19.38 31 16943 5362 110566963
Blood glucose increased 79.80 19.38 100 16874 132396 110439929
Injury associated with device 77.06 19.38 28 16946 4361 110567964
Illness 76.86 19.38 78 16896 82093 110490232
Off label use 76.51 19.38 440 16534 1499745 109072580
Product tampering 75.62 19.38 17 16957 462 110571863
Injection site mass 75.32 19.38 47 16927 24566 110547759
Hunger 72.67 19.38 30 16944 6574 110565751
Increased appetite 68.14 19.38 37 16937 14940 110557385
Inappropriate schedule of product administration 67.59 19.38 116 16858 203521 110368804
Optic ischaemic neuropathy 67.42 19.38 25 16949 4122 110568203
Exposure via skin contact 66.92 19.38 35 16939 13112 110559213
Euglycaemic diabetic ketoacidosis 65.10 19.38 33 16941 11590 110560735
Injection site hypersensitivity 63.69 19.38 21 16953 2450 110569875
Accidental overdose 59.36 19.38 55 16919 51779 110520546
Flatulence 55.25 19.38 53 16921 52096 110520229
Small intestinal obstruction 50.71 19.38 41 16933 32172 110540153
Pyrexia 49.91 19.38 39 16935 898226 109674099
Blood glucose decreased 49.56 19.38 39 16935 29449 110542876
Hypoglycaemia 49.27 19.38 74 16900 116030 110456295
Pneumonia 47.53 19.38 39 16935 876675 109695650
Injection site irritation 46.28 19.38 20 16954 4904 110567421
Pancreatitis 46.09 19.38 64 16910 93469 110478856
Neutropenia 45.73 19.38 3 16971 374617 110197708
Pruritus 45.41 19.38 193 16781 581367 109990958
Dry skin 44.80 19.38 68 16906 107585 110464740
Feeding disorder 44.21 19.38 32 16942 21330 110550995
Anaemia 43.28 19.38 15 16959 547071 110025254
General physical health deterioration 38.54 19.38 9 16965 425286 110147039
Diabetic ketoacidosis 37.63 19.38 39 16935 42019 110530306
Starvation ketoacidosis 37.46 19.38 9 16965 329 110571996
Product dose omission in error 37.16 19.38 30 16944 23482 110548843
Accidental exposure to product 37.10 19.38 42 16932 49966 110522359
Weight decreased 37.01 19.38 156 16818 467901 110104424
Intercepted product dispensing error 35.56 19.38 8 16966 218 110572107
Colitis ischaemic 35.39 19.38 26 16948 17724 110554601
Ketoacidosis 35.32 19.38 21 16953 10066 110562259
Toxicity to various agents 34.97 19.38 15 16959 480540 110091785
Sensitive skin 34.64 19.38 15 16959 3697 110568628
Cholelithiasis 33.67 19.38 45 16929 63377 110508948
Injection site warmth 33.59 19.38 25 16949 17380 110554945
Intestinal ischaemia 32.94 19.38 24 16950 16155 110556170
Dehydration 32.90 19.38 106 16868 279405 110292920
Sleep disorder due to a general medical condition 32.41 19.38 40 16934 52072 110520253
Food craving 32.28 19.38 12 16962 1991 110570334
Intentional dose omission 30.43 19.38 25 16949 20055 110552270
Eye irritation 29.89 19.38 31 16943 33421 110538904
Infusion related reaction 29.19 19.38 11 16963 381151 110191174
Abdominal pain 28.89 19.38 155 16819 512834 110059491
Injection site coldness 28.03 19.38 6 16968 129 110572196
Neurodermatitis 27.85 19.38 12 16962 2920 110569405
Thrombocytopenia 26.83 19.38 10 16964 348875 110223450
Completed suicide 26.68 19.38 3 16971 242378 110329947
Confusional state 26.42 19.38 20 16954 468660 110103665
Systemic lupus erythematosus 25.96 19.38 4 16970 254334 110317991
Injection site vesicles 25.93 19.38 13 16961 4458 110567867
Product use issue 25.58 19.38 8 16966 311687 110260638
Haemoglobin decreased 25.19 19.38 4 16970 248723 110323602
Platelet count decreased 25.00 19.38 3 16971 230440 110341885
Stomatitis 23.92 19.38 6 16968 270236 110302089
Intercepted product selection error 23.80 19.38 4 16970 21 110572304
Hypertension 23.71 19.38 26 16948 510058 110062267
Gastrooesophageal reflux disease 23.70 19.38 71 16903 179905 110392420
Skin swelling 23.64 19.38 15 16959 8065 110564260
Decreased appetite 23.61 19.38 139 16835 475707 110096618
Wound 23.23 19.38 4 16970 234433 110337892
Treatment failure 22.96 19.38 7 16967 277227 110295098
Product storage error 22.85 19.38 22 16952 21706 110550619
Skin burning sensation 22.77 19.38 22 16952 21803 110550522
Vision blurred 22.05 19.38 56 16918 128966 110443359
Joint swelling 21.22 19.38 22 16952 442823 110129502
Food interaction 21.08 19.38 9 16965 2143 110570182
Therapy cessation 21.06 19.38 30 16944 44827 110527498
Hypovolaemia 21.03 19.38 21 16953 21653 110550672
Intentional product use issue 21.00 19.38 6 16968 247900 110324425
Pancreatitis acute 20.84 19.38 35 16939 60239 110512086
Suicidal ideation 20.66 19.38 45 16929 93892 110478433
Fluid intake reduced 20.51 19.38 13 16961 6973 110565352
Lower respiratory tract infection 20.38 19.38 6 16968 243100 110329225
Hypophagia 20.15 19.38 32 16942 52594 110519731
Systolic hypertension 20.15 19.38 7 16967 957 110571368
Musculoskeletal stiffness 19.92 19.38 9 16965 279813 110292512
Eczema 19.90 19.38 38 16936 72255 110500070
Oedema peripheral 19.86 19.38 13 16961 328647 110243678
Lipase increased 19.81 19.38 19 16955 18653 110553672
Product preparation error 19.61 19.38 15 16959 10864 110561461

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BX16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA MoA N0000000152 G-Protein-linked Receptor Interactions
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D000097789 Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000178480 GLP-1 Receptor Agonist
FDA EPC N0000194015 Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:64088 incretin mimetic
CHEBI has role CHEBI:71196 glucagon-like peptide-1 receptor agonist
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:194187 gastric inhibitory polypeptide receptor agonist

Related Drugs by ATC class:

A10BX Other blood glucose lowering drugs, excl. insulins 6 drugs
benfluoreximegliminmitiglinidenateglinidepramlintiderepaglinide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Chronic weight management indication 414916001 DOID:9970
Multiple endocrine neoplasia, type 2 contraindication 61808009
Medullary thyroid carcinoma contraindication 255032005 DOID:3973




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 9474780 Jan. 5, 2036 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12453755 June 14, 2039 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 11918623 June 14, 2039 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12629404 June 14, 2039 A METHOD FOR TREATING OBESITY BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12343382 July 22, 2039 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12453758 July 22, 2039 TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS 12616740 July 22, 2039 TREATMENT OF OBESITY BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS 12295987 Dec. 30, 2041 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Nov. 8, 2026 NEW PRODUCT
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
12.5MG/0.5ML (12.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
15MG/0.5ML (15MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
15MG/0.5ML (15MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
50MG/2.4ML (20.8MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
60MG/2.4ML (25MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS May 13, 2027 NEW CHEMICAL ENTITY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Oct. 18, 2027 LABELING REVISIONS RELATED TO CLINICAL STUDIES
10MG/0.5ML (10MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
10MG/0.5ML (10MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
10MG/2.4ML (4.17MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
10MG/2.4ML (4.17MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
12.5MG/0.5ML (12.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
15MG/0.5ML (15MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
2.5MG/0.5ML (2.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
20MG/2.4ML (8.33MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
20MG/2.4ML (8.33MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
30MG/2.4ML (12.5MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
30MG/2.4ML (12.5MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
40MG/2.4ML (16.7MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
40MG/2.4ML (16.7MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
50MG/2.4ML (20.8MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
50MG/2.4ML (20.8MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
5MG/0.5ML (5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
60MG/2.4ML (25MG/ML) ZEPBOUND ELI LILLY AND CO N217806 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
60MG/2.4ML (25MG/ML) ZEPBOUND KWIKPEN ELI LILLY AND CO N217806 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND ELI LILLY AND CO N217806 March 28, 2024 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
7.5MG/0.5ML (7.5MG/0.5ML) ZEPBOUND (AUTOINJECTOR) ELI LILLY AND CO N217806 Nov. 8, 2023 RX SOLUTION SUBCUTANEOUS Dec. 20, 2027 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY
10MG/0.5ML (10MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
10MG/0.5ML (10MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
10MG/2.4ML (4.17MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
10MG/2.4ML (4.17MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
2.5MG/0.5ML (2.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
20MG/2.4ML (8.33MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
20MG/2.4ML (8.33MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
30MG/2.4ML (12.5MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
30MG/2.4ML (12.5MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
40MG/2.4ML (16.7MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
40MG/2.4ML (16.7MG/ML) MOUNJARO KWIKPEN ELI LILLY AND CO N215866 Jan. 20, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
50MG/2.4ML (20.8MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
5MG/0.5ML (5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
5MG/0.5ML (5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
60MG/2.4ML (25MG/ML) MOUNJARO ELI LILLY AND CO N215866 Jan. 7, 2026 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO ELI LILLY AND CO N215866 July 28, 2023 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION
7.5MG/0.5ML (7.5MG/0.5ML) MOUNJARO (AUTOINJECTOR) ELI LILLY AND CO N215866 May 13, 2022 RX SOLUTION SUBCUTANEOUS Dec. 19, 2028 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST Ki 8.37 SCIENTIFIC LITERATURE DRUG LABEL
Gastric inhibitory polypeptide receptor GPCR AGONIST Ki 9.87 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
CHEMBL4297839 ChEMBL_ID
11429 IUPHAR_LIGAND_ID
DB15171 DRUGBANK_ID
1351584008 SNOMEDCT_US
4041425 VANDF
C5139934 UMLSCUI
D000098860 MESH_DESCRIPTOR_UI
CHEBI:194186 CHEBI
D11360 KEGG_DRUG
10849 INN_ID
2023788-19-2 SECONDARY_CAS_RN
166567236 PUBCHEM_CID
359156 MMSL
40683 MMSL
d09892 MMSL
019067 NDDF
OYN3CCI6QE UNII
2601723 RXNORM
OYN3CCI6QE INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-0152 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-0152 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-0243 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-0243 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1152 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1152 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1214 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1214 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1243 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1243 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1340 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1340 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1423 INJECTION, SOLUTION 12.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-1423 INJECTION, SOLUTION 12.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1457 INJECTION, SOLUTION 15 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1457 INJECTION, SOLUTION 15 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1460 INJECTION, SOLUTION 12.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1460 INJECTION, SOLUTION 12.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1471 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1471 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1484 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1484 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1495 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1495 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1506 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-1506 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-2002 INJECTION, SOLUTION 15 mg SUBCUTANEOUS NDA 36 sections
Zepbound HUMAN PRESCRIPTION DRUG LABEL 1 0002-2002 INJECTION, SOLUTION 15 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-2214 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections
MOUNJARO HUMAN PRESCRIPTION DRUG LABEL 1 0002-2214 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 36 sections